Bronchial Asthma: Definition,Pathophysiology and ManagementMarko Makram
Definition and Pathophysiology of Asthma in addition to classification and recent updates in the management of asthma based on GINA-2019 Guidelines, by Dr. Marco Makram.
Brief summary on gold 2019 guidelines on copdMarko Makram
The document summarizes updates from the 2019 Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines. It defines COPD and risk factors, outlines methods for diagnosis and assessment using spirometry, CAT and mMRC scales. Treatment approaches are discussed including bronchodilators, inhaled corticosteroids, and new biomarkers like blood eosinophil counts to predict treatment responses. Treatment algorithms are provided for managing stable COPD based on symptoms and exacerbation risks.
Chemipharm's core values focus on integrity, quality, and customer service. They strive to conduct business with honesty, deliver high-quality products, and provide excellent service to their customers. The company aims to uphold these values in all aspects of their operations.
8 competitive medical facts about notussilMarko Makram
Notussil is a central antitussive that acts directly on the cough center in the medulla oblongata to inhibit coughing. Unlike codeine, it is non-narcotic and does not cause respiratory depression or dependence. It inhibits inflammatory mediators that stimulate peripheral coughing and also has a bronchorelaxant effect. It can be used safely for chronic bronchitis unlike other cough suppressants as it does not interfere with mucociliary clearance. Notussil has a rapid onset of action within 20-30 minutes and is as effective as codeine for treating coughs without the side effects or risk of dependency.
Bronchial Asthma: Definition,Pathophysiology and ManagementMarko Makram
Definition and Pathophysiology of Asthma in addition to classification and recent updates in the management of asthma based on GINA-2019 Guidelines, by Dr. Marco Makram.
Brief summary on gold 2019 guidelines on copdMarko Makram
The document summarizes updates from the 2019 Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines. It defines COPD and risk factors, outlines methods for diagnosis and assessment using spirometry, CAT and mMRC scales. Treatment approaches are discussed including bronchodilators, inhaled corticosteroids, and new biomarkers like blood eosinophil counts to predict treatment responses. Treatment algorithms are provided for managing stable COPD based on symptoms and exacerbation risks.
Chemipharm's core values focus on integrity, quality, and customer service. They strive to conduct business with honesty, deliver high-quality products, and provide excellent service to their customers. The company aims to uphold these values in all aspects of their operations.
8 competitive medical facts about notussilMarko Makram
Notussil is a central antitussive that acts directly on the cough center in the medulla oblongata to inhibit coughing. Unlike codeine, it is non-narcotic and does not cause respiratory depression or dependence. It inhibits inflammatory mediators that stimulate peripheral coughing and also has a bronchorelaxant effect. It can be used safely for chronic bronchitis unlike other cough suppressants as it does not interfere with mucociliary clearance. Notussil has a rapid onset of action within 20-30 minutes and is as effective as codeine for treating coughs without the side effects or risk of dependency.
8 competitive medical facts about notussilMarko Makram
Notussil (Cloperastine) is a central antitussive that acts directly on the cough center in the medulla oblongata to suppress coughing. Unlike codeine, it is non-narcotic and does not cause respiratory depression or dependence. It inhibits inflammatory mediators that stimulate peripheral cough receptors and exhibits bronchorelaxant properties. It can be safely used in chronic bronchitis without interfering with mucociliary clearance. Notussil has a rapid onset of action within 20-30 minutes and is as effective as codeine for treating coughs from various causes without the side effects of dependency. It is also superior to Butamirate in reducing cough frequency and intensity during both the day and night
8 competitive medical facts about notussilMarko Makram
Notussil (Cloperastine) is a central antitussive that acts directly on the cough center in the medulla oblongata to suppress coughing. Unlike codeine, it is non-narcotic and does not cause respiratory depression or dependence. It inhibits inflammatory mediators that stimulate peripheral cough receptors and exhibits bronchorelaxant properties. It can be safely used in chronic bronchitis unlike other cough suppressants as it does not interfere with mucociliary clearance. Notussil has a rapid onset of action within 20-30 minutes and is as effective as codeine for treating coughs without the side effects, and is superior to Butamirate for reducing daytime and nighttime cough frequency and
8 competitive medical facts about notussil®Marko Makram
Notussil is a central antitussive that acts directly on the cough center in the brain and inhibits inflammatory mediators that cause coughing. Unlike codeine, it is non-narcotic and does not cause respiratory depression or dependence. It has a fast onset of action within 20-30 minutes, is as effective as codeine for treating coughs without the side effects, and is superior to Butamirate for reducing daytime and nighttime coughing.
8 competitive medical facts about notussil®Marko Makram
Notussil is a central antitussive that acts directly on the cough center in the brain and inhibits inflammatory mediators that cause coughing. Unlike codeine, it is non-narcotic and does not cause respiratory depression or dependence. It has a fast onset of action within 20-30 minutes, is as effective as codeine for treating coughs without the side effects, and is superior to Butamirate for reducing daytime and nighttime coughing.
7 competitive medical facts about notussil®Marko Makram
Notussil is a central antitussive medication that acts directly on the cough center in the brain. Unlike codeine, it is non-narcotic and does not cause respiratory depression or dependence. It has antihistamine and bronchodilating properties. Notussil does not interfere with mucus clearance so it can be used safely for chronic bronchitis unlike other cough suppressants. It starts working within 20-30 minutes and is as effective as codeine for treating coughs without the side effects or risk of dependency. Notussil is also superior to Butamirate for reducing daytime and nighttime cough frequency and intensity.
1. Recent guidelines from JNC 8 (2014) and ASH (2013) recommend ARBs as first-line treatment for hypertension, especially for patients with compelling indications like diabetes or chronic kidney disease.
2. Irbesartan has higher bioavailability than other ARBs, requiring no dose adjustments in renal, hepatic or elderly patients. Studies show irbesartan more effectively lowers blood pressure compared to losartan, valsartan, and enalapril.
3. The IDNT and IRMA-2 trials demonstrate irbesartan's superior renoprotective effects. IDNT showed a 20-23% reduced risk of doubling serum creatinine or end-
Analysis & assessment of kemirica® relative toMarko Makram
Evaluation of top generic Pregabalines in the Egyptian market in addition to highlighting the relation between change in prices and demand due to recent changes in the prices of medicine in Egypt.
8 competitive medical facts about notussilMarko Makram
Notussil (Cloperastine) is a central antitussive that acts directly on the cough center in the medulla oblongata to suppress coughing. Unlike codeine, it is non-narcotic and does not cause respiratory depression or dependence. It inhibits inflammatory mediators that stimulate peripheral cough receptors and exhibits bronchorelaxant properties. It can be safely used in chronic bronchitis without interfering with mucociliary clearance. Notussil has a rapid onset of action within 20-30 minutes and is as effective as codeine for treating coughs from various causes without the side effects of dependency. It is also superior to Butamirate in reducing cough frequency and intensity during both the day and night
8 competitive medical facts about notussilMarko Makram
Notussil (Cloperastine) is a central antitussive that acts directly on the cough center in the medulla oblongata to suppress coughing. Unlike codeine, it is non-narcotic and does not cause respiratory depression or dependence. It inhibits inflammatory mediators that stimulate peripheral cough receptors and exhibits bronchorelaxant properties. It can be safely used in chronic bronchitis unlike other cough suppressants as it does not interfere with mucociliary clearance. Notussil has a rapid onset of action within 20-30 minutes and is as effective as codeine for treating coughs without the side effects, and is superior to Butamirate for reducing daytime and nighttime cough frequency and
8 competitive medical facts about notussil®Marko Makram
Notussil is a central antitussive that acts directly on the cough center in the brain and inhibits inflammatory mediators that cause coughing. Unlike codeine, it is non-narcotic and does not cause respiratory depression or dependence. It has a fast onset of action within 20-30 minutes, is as effective as codeine for treating coughs without the side effects, and is superior to Butamirate for reducing daytime and nighttime coughing.
8 competitive medical facts about notussil®Marko Makram
Notussil is a central antitussive that acts directly on the cough center in the brain and inhibits inflammatory mediators that cause coughing. Unlike codeine, it is non-narcotic and does not cause respiratory depression or dependence. It has a fast onset of action within 20-30 minutes, is as effective as codeine for treating coughs without the side effects, and is superior to Butamirate for reducing daytime and nighttime coughing.
7 competitive medical facts about notussil®Marko Makram
Notussil is a central antitussive medication that acts directly on the cough center in the brain. Unlike codeine, it is non-narcotic and does not cause respiratory depression or dependence. It has antihistamine and bronchodilating properties. Notussil does not interfere with mucus clearance so it can be used safely for chronic bronchitis unlike other cough suppressants. It starts working within 20-30 minutes and is as effective as codeine for treating coughs without the side effects or risk of dependency. Notussil is also superior to Butamirate for reducing daytime and nighttime cough frequency and intensity.
1. Recent guidelines from JNC 8 (2014) and ASH (2013) recommend ARBs as first-line treatment for hypertension, especially for patients with compelling indications like diabetes or chronic kidney disease.
2. Irbesartan has higher bioavailability than other ARBs, requiring no dose adjustments in renal, hepatic or elderly patients. Studies show irbesartan more effectively lowers blood pressure compared to losartan, valsartan, and enalapril.
3. The IDNT and IRMA-2 trials demonstrate irbesartan's superior renoprotective effects. IDNT showed a 20-23% reduced risk of doubling serum creatinine or end-
Analysis & assessment of kemirica® relative toMarko Makram
Evaluation of top generic Pregabalines in the Egyptian market in addition to highlighting the relation between change in prices and demand due to recent changes in the prices of medicine in Egypt.